The Effect of Kynureninase on Cancer Treatment
DOI:
https://doi.org/10.61173/dn3jy275Keywords:
immunotherapy, immunosuppression, ky-nurenineAbstract
At present, cancer is still one of the most common lethal diseases in human beings. The traditional treatment of cancer has great side effects on human body, and more advanced treatment schemes need to be found to improve the survival rate of cancer. Nowadays, immunotherapy and targeted therapy are very promising directions. In immunotherapy, most of them are immune checkpoint inhibitors, cancer vaccines, cell therapy, etc., and few biological enzymes have been applied in cancer treatment. This paper analyzes the research on kynureninase, and proves that kynurenine accumulation is one of the important factors that lead to the occurrence of tumors. Combined with kynureninase, it can have a significant effect in the treatment of large B16-F10 melanoma, 4T1 breast cancer or CT26 colon cancer tumors. It can provide reference for the future research of immunotherapy, and the source problem of kynureninase has not been solved. Future research can focus on the development and optimization of humanized enzyme.
References
[1] Crosby D, Bhatia S, Brindle K M, et al., “Early detection of cancer,” Science, vol. 375, no. 6586, p. eaay9040, 2022.
[2] Xia C, Dong X, Li H, et al., “Cancer statistics in China and United States, 2022: Profiles, trends, and determinants,” Chinese Medical Journal, vol. 135, no. 5, pp. 584–590, 2022.
[3] Yan Z, Yao S, Wang Z, et al., “Treatment of extranodal NK/T-cell lymphoma: From past to future,” Frontiers in Immunology, vol. 14, 2023.
[4] Belli C, Trapani D, Viale G, et al., “Targeting the microenvironment in solid tumors,” Cancer Treatment Reviews, vol. 65, 2018.
[5] Feng X, Meng M, Li H, et al., “T-cell dysfunction in natural killer/T-cell lymphoma,” Oncoimmunology, vol. 12, no. 1, p. 11, 2023.
[6] Ala M, “The footprint of kynurenine pathway in every cancer: A new target for chemotherapy,” European Journal of Pharmacology, p. 173921, 2021.
[7] Puccetti P, Francesca, et al., “Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers,” PLoS One, 2015.
[8] Yi S, Yang M, Duan K, “Immune-mediated metabolic kynurenine pathways are involved in the postoperative cognitive dysfunction after cardiopulmonary bypass,” The Thoracic and Cardiovascular Surgeon, vol. 63, no. 07, pp. 618–623, 2015.
[9] Metz R, Rust S, Duhadaway J B, et al., “IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan,” Oncoimmunology, vol. 1, no. 9, pp. 1460–1468, 2012.
[10] Lu Z, Zhang C, Zhang J, et al., “The kynurenine pathway and indole pathway in tryptophan metabolism influence tumor progression,” Cancer Medicine, vol. 14, no. 6, 2025.
[11] Xie D L, Wu J, Lou Y L, et al., “Tumor suppressor TSC1 is critical for T-cell anergy,” Proceedings of the National Academy of Sciences, 2012.
[12] Timosenko E, Ghadbane H, Silk J D, et al., “Nutritional stress induced by tryptophan-degrading enzymes results in ATF4-dependent reprogramming of the amino acid transporter profile in tumor cells,” Cancer Research, vol. 76, no. 21, 2016.
[13] Triplett T A, Garrison K C, Nicholas M, et al., “Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme,” Nature Biotechnology, 2018.
[14] Cervenka I, Agudelo L Z, Ruas J L, “Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health,” Science, vol. 357, no. 6349, p. eaaf9794, 2017.
[15] Cory M, Vladimir L, Lena B, et al., “Three-dimensional structure of kynureninase from Pseudomonas fluorescens,” Biochemistry, vol. 43, no. 5, p. 1193, 2004.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
